Penn Pharma Further Expands Capabilities with Contained Roller Compaction Technology

Pharmaceutical manufacturer, Penn Pharma has invested in a contained Gerteis Mini-Pactor further expanding its service offering at its world leading solid dose contained manufacturing facility at the Tredegar site in South Wales.

Penn Pharma has 20 years of experience in the use of roller compactor technology for pharmaceutical manufacturing and as a company, understands the importance of applying this valuable technology to address specific technical challenges.

The contained roller compactor will increase Penn’s ability to provide additional solutions for growing market demand for the processing and manufacturing of solid dosage forms containing potent molecules.

Roller compaction is a process that provides a granulation method for materials that are heat and moisture sensitive. It avoids the use of liquid and high temperatures associated with wet granulation and subsequent drying methods. The Gerteis Mini-Pactor offers a patented proven design that enhances powder flow as well as effective containment using skan isolator technology and integrated cleaning systems. The process is easily scaleable facilitating shorter and less costly development programmes.

The contained Gerteis Mini-Pactor roller compactor is a valuable addition to Penn’s vision of becoming the partner of choice for the development and manufacture of solid oral dose forms of highly potent products.

Mark Dean-Netscher, Vice President of International Operations at Penn Pharma said: “Our contained manufacturing facility is world class and additional investment in roller compaction capacity allows us to offer  even more development and manufacturing solutions to our customers.”

Mark continued: “We have recognised and responded to a growing need within the industry for continuous granulation methods by developing our dry granulation capabilities. This roller compactor can be used from 1 kg development scale up to 100 kg per hour at production scale, without the need for additional scale up work. This will significantly reduce our clients’ costs and allow products to be developed and delivered to market far quicker.”